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Abstract
Background: In recent decades, benzodiazepine (BZD) prescriptions have been called into question in most
European countries by physicians and health authorities alike, and guidelines on medical indications and treatment
duration have been established to avoid long-term use and dependency. In France, many public policy measures
have been implemented as BZDs are among the most prescribed medications. General practitioners (GPs) were
identified by the Caisse d’Assurance Maladie (the French public health insurance fund) as high prescribers for these
drugs. In this context, the aim of the study was to determine GPs’ rates and to identify correlates of BZD and Z-
drugs prescribing.
Methods: Data on patient characteristics, diagnoses and BZD prescriptions were drawn from French GPs’ electronic
medical records. These were accessed via the database which the Société Française de Médecine Générale, the
French Society of General Practice, has been compiling since 1993 in a network of 90 GPs working mainly in solo
practices. The participants in this network routinely register data in their daily practice. The present study examined
51,216 patients from 52 GP practices and we performed a multivariate logistic regression. The dependent variable
was whether a patient was prescribed BZD at least once during 2006.
Results: In the present study, 12.5% of patients older than 18 were prescribed BZDs at least once during 2006 and
the average (SD) was 2.6 (2.4) BZD prescriptions/patient/year. The adjusted odds (confidence interval) of having at
least one BZD prescription were 1.20 (1.10 - 1.30) in patients older than 65; 1.05 (1.01 - 1.10) in women; 1.25 (1.17 -
1.33) in patients with associated comorbidities (cardiovascular diseases) and 1.76 (1.62 - 1.92) in heavy consumers
of health care (more than 4 consultations with a GP per year).
Conclusions: The present study showed the persistence of high rates of BZD prescription by GPs, particularly in
women and older patients, which highlights the difficulties of implementing effective public policies and the
necessity of using new approaches enabling doctors and patients to understand the true relative advantages,
disadvantages, and consequences of using these drugs and of non-pharmaceutical treatments.
Background
In recent decades, BZD prescriptions have been called
into question in most European countries by physicians
and health authorities alike, and guidelines on medical
indications and treatment duration have been estab-
lished to avoid long-term use and dependency [1,2]. In
France, many public policy measures have been imple-
mented as BZDs are among the most prescribed medi-
cations [3]. The Agence Française de Sécurité Sanitaire
e td e sP r o d u i t sd eS a n t é(AFSSAPS), an institution in
charge of the risk-benefit assessment of the use of
healthcare products, initiated various actions to promote
the safe use of BZDs. These actions, which were sup-
ported by working groups and ad hoc surveys, led to the
establishment of good practice recommendations [4].
Yet, in a recent report on the proper use of psychotro-
pic medications, it was shown that these drugs were
often inappropriately prescribed (in terms of users, indi-
cations, duration of treatment) [5]. General practitioners
(GPs) were identified by the Caisse d’Assurance Maladie
(the French public health insurance fund) as high pre-
scribers for these drugs [6]. Gaining insight into GPs’
BZD prescribing seemed appropriate in this context.
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to identify correlates of BZD and Z-drugs prescribing in
a large database in general practice in France.
Methods
General practitioner sampling
Data on patients, diseases and related health problems
and BZD prescriptions were drawn from French GPs’
electronic medical records. These were accessed via the
database which the Société Française de Médecine Gén-
érale, the French Society of General Practice, has been
compiling since 1993 in a network of 90 GPs working
mainly in solo practices (SFMG-DB). The participants in
this network routinely register data in their daily prac-
tice. They are largely representative of the French GP
population [7], although a comparison with data from
the Ministry of Health shows that doctors working in
rural areas were under-represented [8]. We studied the
practices of the 52 GPs for whom complete information
with regard to prescriptions was available during 2006
(Commission Nationale de l’Informatique et des Libertés
(CNIL) - approval n° 311668).
Patient registration
The 52 GPs had cared for a total of 75,367 patients
whose age and sex distribution did not differ signifi-
cantly from that of the population as a whole. For the
present data-based study, we only selected patients older
than 18, which gave us a sample of 51,216 patients.
Codes for diseases and related health problems
In the SFMG-DB, diseases and related health problems
are coded using the Dictionary of Consultation Results
(DCR), which has been validated in France [9]. The cor-
responding codes in the International Classification of
Diseases, 10th Revision, Clinical Modifications (ICD-10-
CM) were also mentioned. The diseases and related
health problems selected as indications for BZD are
mentioned in Table 1. We also collected data on other
diseases and related health problems that are frequently
encountered in general practice (in the top 10 with
insomnia/anxiety/depression) [7] (also see Table 1).
BZD prescriptions
In the SFMG-DB, prescriptions are coded according to
the Anatomical Therapeutic Chemical (ATC) Classifica-
tion System (WHO, 2006). We retained four therapeutic
categories: (i) BZD-derivative anxiolytics: ATC group
N05BA (e.g., diazepam, oxazepam, lorazepam); (ii) BZD-
derivative hypnotics and sedatives: ATC group N05CD
(e.g., flurazepam, nitrazepam, temazepam); (iii) BZD-
derivative anti-epileptics: ATC group N03AE (e.g., clo-
nazepam); and (iv) Z-drugs: ATC group N05CF (e.g.,
zopiclone and zolpidem).
Data analysis
The chi-square test and Student’s t test were used to
compare cross-classified and continuous variables,
respectively. We performed am u l t i v a r i a t el o g i s t i c
regression, and the following covariates were introduced
into the model: age (<65/≥65), gender (M/F), level of
healthcare consumption (<4/≥4 consultations/year) and
presence of comorbidities [at least one consultation for
anxiety and/or depression and/or insomnia during the
year (Y/N), at least one consultation for hypertension
and/or hyperlipidemia and/or type 2 diabetes during the
year (Y/N) and at least one consultation for lumbar
region pain and/or arthrosis and/or arthropathies during
the year (Y/N)]. The interactions between all these cov-
ariates were tested and included in the model when sta-
tistically significant. The dependent variable was
whether a patient was prescribed BZD at least once dur-
ing 2006. The data had a two-level hierarchical struc-
ture, with individuals nested in GPs. Within GP
clustering was taken into account by estimating the
fixed coefficients and their standard errors using the
method of generalised estimated equation (GEE) [10].
SAS software was used for the analyses [11].
Results
Patient characteristics
Patient characteristics in the study population (n = 51,216)
are summarised in Table 2. In our patient sample, 12.5%
( n=6 , 4 0 5 )w e r ep r e s c r i b e dB Z D sa tl e a s to n c ed u r i n g
2006, and the average (SD) number of consultations per
patient with at least one BZD prescription was 2.6 (2.4).
Figure 1 presents the distribution of BZD prescriptions -
16,886 in all - according to the therapeutic categories. The
most frequently prescribed medications by French GPs
Table 1 Corresponding codes in the Dictionary of
Consultation Results and the International Classification
of Diseases, 10th Revision, Clinical Modifications
disease Dictionary of
consultation result
(DCR)
International classification
of diseases (ICD-10-CM)
Insomnia DCR 742 ICD F51.0
Stress reaction DCR 752 ICD F43.9
Mild depressive DCR 739 ICD F32.0
Depression DCR 727 ICD F32.9
Anxiety DCR 859 ICD F41.9
Hypertension DCR 826 ICD I10
Hyperlipidemia DCR 740 ICD E78.5
Type 2 diabetes DCR 818 ICD E11
Lumbar region
pain
DCR 850 ICD M54.5
Arthrosis DCR 715 ICD M19.9
Arthropaties/
Periarthropathies
DCR 828 ICD M25.9
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Page 2 of 6were from the ATC groups N05BA (e.g., diazepam, oxaze-
pam, lorazepam), which accounted for 64.9% of all BZD
prescriptions, and N05CF (e.g., zopiclone and zolpidem),
which accounted for 22.3%. Medication from the ATC
group N05CF was over-represented in patients 65 and
older (24.4% vs. 21.1% in patients under 65).
Univariate analyses
Table 3 presents a comparison of the descriptive charac-
teristics of patients in the study population according to
whether or not they were prescribed BZDs. Anxiety,
insomnia and depression were coded in respectively
16.9, 20.9 and 41.3% of the patients who were pre-
scribed BZDs. Patients of 65 and older were over-repre-
sented in this latter group compared with those who
were not prescribed BZDs (27.1% vs. 16%, P < 0.001).
Table 4 compares the descriptive characteristics of
patients who were prescribed BZDs according to age
(under or over 65). Among patients 65 and older, 19.5%
were prescribed BZDs at least once.
Logistic regression model
The detailed results of the logistic regression model are
summarised in Table 5. The adjusted odds (confidence
interval) of having at least one BZD prescription were
1.05 (1.01 - 1.10) in women, 1.25 (1.17 - 1.33) in
patients with associated co-morbidities (e.g., cardiovas-
cular diseases), and 1.76 (1.62 - 1.92) in heavy consu-
mers of healthcare (more than four consultations with a
GP per year). Even after adjustment for the different
covariates introduced into the model, the effect of age
on BZD prescriptions was still significant (adjusted OR
= 1.20 (1.10 - 1.30)).
Discussion
Despite the efforts made by healthcare authorities, phy-
sicians’ unions and healthcare professionals to curb BZD
use, our study still shows a rate of BZD prescription of
around 12%, which is close to what it was several dec-
ades ago [6].
Age was a main determinant of BZD prescribing:
elderly patients received more BZD prescriptions than
younger patients. This finding was consistent with data
from other studies [12-15]. It is not explained, as sug-
gested by Morin et al [16], by more frequent visits with
GPs since the association was still significant after con-
trolling in our model for the effect of the number of
consultations with a GP per year. Other reasons could
explain BZD prescribing in elderly people, in particular
the perception of elderly people with regard to the pro-
cess of ageing and the use of BZDs in this process. Col-
lin showed that older people considered themselves to
be undergoing a process of deterioration and that only
pharmaceuticals, in particular BZDs, could treat the
related stress and anxiety [17]. Moreover, physicians
also view the process of ageing as one of loss, marked
by physical and mental decline as well as by social and
emotional isolation [18]. From this perspective, BZDs
are seen by doctors as “compassion pharmaceuticals”
that serve to relieve the suffering of elderly patients.
This contrasts with the general message put out by the
experts, which focuses on the necessity of reducing BZD
prescriptions for elderly people because of their consid-
erable side effects [16].
Being a female was also significantly predictive in our
model. This result was consistent with prior reports
[19,20]. It has been shown that most female users took
BZDs to treat anxiety (ranging from fears of dying to
claustrophobia), to be “calm” and “relaxed” in daily
situations [21]. According to Van der Waals et al,
Table 2 Patients’ characteristics in the study population
(n = 51,216)
Patients 18+
Mean age in years (SD) 45,7
(18,4)
% of patients of 65 or older 17.5
% females 54,5
Nb consultations/patient/year (SD) 3,2 (2.7)
% patients with > 4 consultations/year 24
Nb consultations/patient/year with at least one prescription
(SD)
2,6 (2.3)
% patients with at least one prescription 91,3
% of patients with at least one BZD prescription 12,5
% patients
- with anxiety 3.7
- with depression 10.3
- with insomnia 4.1
- with cardiovascular diseases 18.2
- with arthropathic diseases 22.4
 
Figure 1 Distribution of BZDs prescriptions in the study
population, 16886 in all, according to the therapeutic
categories.
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not legitimate indications (like headache and general
fatigue) [19]. In a recent study carried out in general
population, it was confirmed that potentially inap-
propriate drug use (all types of drugs confounded)
w e r em o r ec o m m o ni nw o m e n( 2 4 , 6 % )t h a ni nm e n
(19,3%). In particular, female sex was highly associated
with inappropriate psychotropic use (eg, long-acting
BZDs) [20]. BZD withdrawal can be a traumatic pro-
cess for both patients and doctors. This reputation is
largely undeserved if the process is carried out judi-
ciously [22]. Although different approaches have been
assessed, BZD withdrawal remains a key issue that is
still difficult to resolve in routine care [23].
Suffering from somatic chronic disease was also asso-
ciated with BZD prescribing [24]. This could be
explained by the fact that somatic chronic disease causes
anxiety and insomnia [25,26] which are associated with
BZD prescribing [24]. However, the effect that we
detected for somatic diseases was independent of anxiety
and insomnia diagnoses. This finding was also under-
lined by Mant et al. but they did not put forward a clear
explanation [12]. Our hypothesis was that diagnoses of
anxiety and/or insomnia were not always coded in the
database when a BZD was prescribed to patients with a
somatic disease.
Finally, our findings showed that being a heavy con-
sumer of health care was also associated with BZD
Table 3 Comparison of the descriptive characteristics of patients in the study population (n = 51,216) according to
whether or not they were prescribed BZDs
Patients 18+ Without BZDs prescriptions (n = 44,811) With BZDs prescriptions (n = 6,405) P value
Mean age in years (SD) 44.5 (18.2) 53.5 (17.1) P < 0.001
% patients of 65 or older 16.0 27.1 P < 0.001
% females 53.1 64.1 P < 0.001
Nb consultations/patient/year (SD) 2.9 (2.4) 5.3 (3.3) P < 0.001
% patients with > 4 consultations/year 19.8 52.6 P < 0.001
% patients
- with anxiety 1.9 16.9 P < 0.001
- with depression 5.8 41.3 P < 0.001
- with insomnia 1.7 20.9 P < 0.001
- with cardiovascular diseases 20.5 36.4 P < 0.001
- with arthropathic diseases 16.8 27.7 P < 0.001
Table 4 Comparison of the descriptive characteristics of patients who were prescribed BZDs (n = 6,405) according to
age (less than 65/65 or more)
Patients 18+ < 65 (n = 4,667) ≥ 65
(n = 1,738)
P value
Mean age (SD) 45.2 (11.5) 75.5 (6.9) P < 0.001
% female 62.7 67.8 P < 0.001
Nb consultations/patient/year (SD) 5.15 (3.4) 5.98 (3.1) P < 0.001
Nb consultations/patient/year with at least one prescription (SD) 4.4 (2.9) 5.0 (2.7) P < 0.001
% patients with > 4 consultations/year 50.0 63.9 P < 0.001
% patients
- with anxiety 17.8 14.5 p = 0.002
- with depression 46.8 26.7 P < 0.001
- with insomnia 17.8 29.2 P < 0.001
- with cardiovascular diseases 24,9 67.3 P < 0.001
- with arthropathic diseases 23.2 39.8 P < 0.001
Mean nb of BZDs prescriptions/year (SD) 2.4 (2.3) 3.3 (2.3) P < 0.001
% patients with at least one prescription of
- N05BA 75.6 66.9 P < 0.001
- N05CD 5.3 6.3 NS
- N03AE 8.1 10.9 P < 0.001
- N05CF 25.9 27.6 NS
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specialist care, in the French health care context in
2006, prevented us from correctly interpreting this
finding. Indeed, patients could consult a specialist (e.g.,
f o rc a r d i o v a s c u l a rd i s e a s e so ra r t h r o p a t h i e s )w i t h o u t
necessarily going through a GP. This causes a substitu-
tion effect between the two types of doctors and
reduces the use of GPs [27]. In our model, we assumed
that if we had adjusted for the number of visits to a
specialist during the year, the independent effect of
heavy healthcare consumption on BZD prescribing
would have disappeared.
Limitations of the study
Firstly, the SFMG-DB does not include information on
the duration of prescribed BZD treatment. Therefore,
we could not distinguish between short-term and con-
tinuous prescriptions. Although this could limit the con-
clusions of our study, our model was capable of
identifying correlates of BZD prescriptions in patients
consulting GPs. Secondly, data on doctors’ characteris-
tics were not available in the SFMG-DB at the time of
our study. This precluded a study of interactions
between patients and doctors in a multilevel approach.
Nevertheless, within GP clustering was taken into
account in the statistical analysis by estimating the fixed
coefficients and their standard errors using the GEE
method. Thirdly, because in 2006 it was not yet manda-
tory for patients to be registered with their GP, we only
had access to information on consulting patients. There-
fore, we should be cautious in comparing the rates of
BZD prescribing of the present study with those of pre-
viously published studies conducted in populations of
patients registered with their GPs.
Conclusions
The findings of our study are consistent with studies on
BZD prescribing in other European countries. BZD pre-
scribing is significantly related to age, gender, chronic
illness and health care consumption. Despite public pol-
icy actions, and good practice recommendations, the
BZD prescribing rate remains the same as several dec-
ades ago. Until now, most of the actions organised by
Health Authorities to decrease BZD use and prescrip-
tions applied to GPs and their prescribing behaviour. As
suggested by Siriwardena et al, new approaches could be
developed enabling doctors and patients to understand
t h et r u er e l a t i v ea d v a n t a g e s ,disadvantages, and conse-
quences of using these drugs on the one hand and of
non-pharmaceutical treatments on the other hand [28].
Finally, an inter-professional dialogue between GPs, psy-
chiatrists, and pharmacists could also provide useful
resources about the use and/or the withdrawal of BZD
by patients [29].
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